#1 Clinical Trials Search in Europe

Tinzaparin Sodium

Tinzaparin Sodium, a low molecular weight heparin (LMWH), is being extensively studied in clinical trials for its potential benefits in treating and preventing various medical conditions. These trials aim to evaluate its effectiveness and safety in different patient populations, including those with cancer, venous thromboembolism, and COVID-19. The research focuses on exploring tinzaparin’s anticoagulant properties and its potential to improve patient outcomes in various clinical scenarios.

Table of Contents

What is Tinzaparin Sodium?

Tinzaparin Sodium, also known by its brand name Innohep®, is a type of medication called a low molecular weight heparin (LMWH). It is an anticoagulant, which means it helps prevent blood clots from forming or growing larger[1]. Tinzaparin is derived from natural heparin through a process called enzymatic hydrolysis, which gives it unique properties compared to other LMWHs[2].

What Conditions Does Tinzaparin Treat?

Tinzaparin is used to treat and prevent various conditions related to blood clots, including:

  • Venous Thromboembolism (VTE): This includes deep vein thrombosis (DVT, blood clots in the legs) and pulmonary embolism (PE, blood clots in the lungs)[1][3]
  • Cancer-associated thrombosis: Tinzaparin is used to prevent and treat blood clots in patients with various types of cancer, including lung cancer, kidney cancer, and colorectal cancer[3][4][5]
  • Pregnancy-related VTE: It’s used to prevent blood clots in women after cesarean section[1]
  • COVID-19-associated thrombosis: Some studies are exploring its use in preventing blood clots in hospitalized COVID-19 patients[2]

How Does Tinzaparin Work?

Tinzaparin works by:

  • Inhibiting blood clotting factors: It primarily inhibits a clotting factor called Factor Xa, which is crucial in the blood clotting process[2]
  • Releasing Tissue Factor Pathway Inhibitor (TFPI): This helps further prevent blood clot formation[2]
  • Potential anti-inflammatory and anti-tumor effects: Some studies suggest tinzaparin may have additional benefits beyond blood clot prevention, especially in cancer patients[4][5]

How is Tinzaparin Administered?

Tinzaparin is typically administered as a subcutaneous injection, which means it’s injected just under the skin. The dosage and duration of treatment can vary depending on the condition being treated:

  • For VTE prevention after surgery: Usually given once daily, starting within 12-24 hours after surgery and continuing for up to 14 days[1]
  • For cancer patients: May be given for extended periods, sometimes up to 6 months or longer[3][6]
  • Common dosages range from 4,500 IU to 14,000 IU per day, depending on the patient’s weight and condition[1][2]

Ongoing Clinical Trials

Several clinical trials are currently exploring new uses for tinzaparin:

  • Preventing cancer recurrence in colorectal cancer patients undergoing surgery[5]
  • Long-term use in lung cancer patients to prevent VTE[3]
  • Use in hospitalized COVID-19 patients to prevent thrombotic complications[2]
  • Improving survival in pancreatic cancer patients[7]

Potential Side Effects

Like all medications, tinzaparin can cause side effects. The most common and important ones include:

  • Bleeding: This can range from minor bleeding (e.g., nosebleeds, bruising) to major bleeding events. It’s important to monitor for any signs of unusual bleeding[5][7]
  • Injection site reactions: Such as pain, redness, or bruising at the injection site
  • Allergic reactions: Although rare, some people may be allergic to tinzaparin
  • Thrombocytopenia: A decrease in blood platelets, which can increase the risk of bleeding

Special Considerations

There are some important points to keep in mind when using tinzaparin:

  • Monitoring: Unlike some other blood thinners, tinzaparin usually doesn’t require routine blood tests to monitor its effects[8]
  • Renal function: Tinzaparin may be safer for patients with kidney problems compared to some other LMWHs, as it’s less dependent on kidney function for clearance[2]
  • Pregnancy: Tinzaparin is often used in pregnancy and postpartum periods when anticoagulation is needed[1]
  • Surgery: If you’re taking tinzaparin and need surgery, make sure to inform your healthcare provider, as you may need to stop the medication temporarily
Aspect Details
Primary Conditions Studied Venous Thromboembolism, Various Cancers (lung, kidney, colorectal), COVID-19
Administration Method Subcutaneous injection
Dosage Range Varies by study; examples include 4,500 IU daily, 175 Anti-Xa IU/kg daily
Treatment Duration Ranges from short-term (during hospitalization) to extended periods (up to 6 months)
Primary Outcomes Measured Incidence of thrombotic events, disease-free survival, progression-free survival
Secondary Outcomes Overall survival, bleeding events, quality of life measures
Potential Benefits Prevention of blood clots, potential anti-tumor effects, improved survival in certain cancers
Main Safety Concerns Risk of bleeding events (major and minor)

FAQ

  • What is Tinzaparin Sodium? Tinzaparin Sodium is a type of low molecular weight heparin (LMWH) used as an anticoagulant. It helps prevent blood clots from forming or growing larger in the blood vessels.
  • In which medical conditions is Tinzaparin Sodium being studied? Tinzaparin Sodium is being studied in various conditions, including venous thromboembolism, cancer (such as lung, kidney, and colorectal cancers), and COVID-19. It's also being investigated for its potential to improve outcomes after surgery.
  • How is Tinzaparin Sodium administered in clinical trials? In most clinical trials, Tinzaparin Sodium is administered as a subcutaneous injection. The dosage and duration of treatment vary depending on the specific study and condition being treated.
  • What are the potential benefits of using Tinzaparin Sodium? Potential benefits include preventing blood clots, reducing the risk of cancer recurrence or spread, and improving overall survival in certain patient populations. Some studies also suggest it may have anti-inflammatory and antiviral properties.
  • Are there any risks associated with Tinzaparin Sodium use in clinical trials? As with any anticoagulant, there is a risk of bleeding events. Clinical trials closely monitor patients for major and minor bleeding events, as well as other potential side effects. The benefits and risks are carefully weighed for each individual patient.

Ongoing Clinical Trials on Tinzaparin Sodium

  • Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness

    Recruiting

    3 1 1 1
    Investigated drugs:
    Denmark Finland Iceland The Netherlands Sweden

  • Study on Preventing Blood Clots in Pancreatic Cancer Patients Using Tinzaparin Sodium and Enoxaparin Sodium During Treatment

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study Comparing Rivaroxaban and Drug Combination for Preventing Blood Clots in Patients with Lower Limb Injuries Requiring Immobilization

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on the Best Antithrombotic Therapy for Patients with Acute Venous Thromboembolism Using Tinzaparin Sodium and Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Preventing Blood Clots in Patients with Advanced Germ Cell Tumors Using Cisplatin and a Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on the Effects of Tinzaparin on Biomarkers in Advanced Ovarian Cancer Patients Receiving Chemotherapy

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Enoxaparin or drug combination versus no anticoagulant treatment for incidental subsegmental pulmonary embolism in cancer patients

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on the Effect of Tinzaparin Sodium on Survival in Patients with Advanced Pancreatic Cancer

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

  • Study on Treatments for Intermediate High-Risk Pulmonary Embolism: Comparing Percutaneous Embolectomy, Ultrasound-Assisted Thrombolysis with Alteplase, and Heparin

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Preventing Blood Clots with Tinzaparin in Patients with Metastatic Colorectal Cancer Starting First-Line Treatment

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal Spain

Glossary

  • Venous Thromboembolism (VTE): A condition where blood clots form in the veins, typically in the legs (deep vein thrombosis) or lungs (pulmonary embolism).
  • Low Molecular Weight Heparin (LMWH): A type of anticoagulant medication derived from unfractionated heparin, used to prevent and treat blood clots.
  • Anticoagulant: A substance that helps prevent blood clots from forming or growing larger in the blood vessels.
  • Subcutaneous injection: An injection given into the fatty tissue just beneath the skin.
  • Metastasis: The spread of cancer cells from the primary tumor to other parts of the body.
  • Thromboprophylaxis: The prevention of blood clot formation, especially in patients at high risk.
  • Disease-free Survival: The length of time after treatment during which no disease is found.
  • Overall Survival: The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Progression-free Survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Anti-Xa activity: A measure of the anticoagulant effect of low molecular weight heparins, based on their ability to inhibit factor Xa in the blood clotting cascade.

References

  1. https://clinicaltrials.gov/study/NCT01321788
  2. https://clinicaltrials.gov/study/NCT05036824
  3. https://clinicaltrials.gov/study/NCT03090880
  4. https://clinicaltrials.gov/study/NCT00293501
  5. https://clinicaltrials.gov/study/NCT01455831
  6. https://clinicaltrials.gov/study/NCT00981903
  7. https://clinicaltrials.gov/study/NCT05178628
  8. https://clinicaltrials.gov/study/NCT00203580